Skip to content

3D printing guide tube assisted penetrating Cervical Microendoscopic Laminoplasty for cervical spondylotic myelopathy

3D printing guide tube assisted penetrating Cervical Microendoscopic Laminoplasty for cervical spondylotic myelopathy: study protocol for a self-control trial

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021170
Enrollment
Unknown
Registered
2019-01-31
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical spondylotic myelopathy

Interventions

Case series:3D printing guide tube

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) conforming to the diagnosis of cervical spondylotic myelopathy; (2) Aged 18-65 years old; (3) imaging findings of 3 or more consecutive or discontinuous segmental lesions; (4) sign informed consent.

Exclusion criteria

Exclusion criteria: (1) there were combined injuries, dislocation and old fractures; (2) pathological fracture, such as osteoporosis and tumor; (3) congenital atlantooccipital deformity; (4) lateral sclerosis of the spinal cord; (5) syringomyelia; (6) spinal cord occupying; (7) no legal capacity or legal capacity is restricted; (8) With strict gravity center, liver, kidney and blood system and other important organ diseases; (9) the researchers considered it inappropriate to participate in any other circumstances of the trial.

Design outcomes

Primary

MeasureTime frame
JOA improvement rate;

Secondary

MeasureTime frame
operation time;Incision length;intraoperative blood loss;incidence of adverse reactions;cervical curvature index;range of motion;spinal canal enlargement;

Countries

China

Contacts

Public ContactChunlin Zhang

The First Affiliated Hospital of Zhengzhou University

michaelfeng1992@163.com+86 13903835325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026